ALK-Abelló A/S

ALK-Abelló A/S

AKABY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$19.85B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
ALK-Abelló A/SALK-Abelló A/S40.70.64%19%2.80.1

Earnings Call Q3 2026

November 17, 2026 - AI Summary

Strong Q3/9-month growth and upgraded full-year outlook confirmed - GOOD, with a cash-flow surprise: Q3 revenue grew 15% in local currencies to DKK 1.76bn, with growth in all regions and tablets up 35% to DKK 999m, essentially a third quarter at ~DKK 1bn; EBIT rose 9% to DKK 469m, though margin slipped to 27% from 28%. For the first 9 months revenue rose 17% in local currencies to DKK 5.3bn, EBIT rose 16% to ~DKK 1.5bn at an unchanged 28% margin, gross profit was DKK 3.6bn/68% vs 67%, and free cash flow was DKK 1.19bn vs DKK 836m, with net debt/EBITDA at -0.7x. Management confirmed the 7 October upgrade: full-year revenue growth 16-17% in local currencies (from 14-16%), EBIT margin ~27% (from 26%), gross margin slightly above 67%, R&D >10% of revenue, CapEx ~DKK 400m, and free cash flow >DKK 1.1bn - already exceeded after 9 months - with tablets growing double-digit, SCIT/SLIT drops single-digit, Anaphylaxis low double-digit, and growth expected >10% in coming years.
Tablets and the pediatric rollout are the core engine, but Europe faces a Germany rebate risk and a Q4 stocking reversal - GOOD/BAD: Global tablets were 57% of Q3 revenue, with Europe +33%, North America +32% and International +47%; Europe total revenue +18% in local currencies, North America +8% to DKK 270m and International +6% to DKK 248m. Pediatric launches are driving growth - house dust mite tablet approved in 36 countries/launched in 24, tree pollen ITULAZAX approved in 20/launched in 14 - with children now >30% of scripts, up from 30% in Q2, progressing toward a 50% ambition, and ALK claims ~50% market share and continued share gains. The tree initiation season is very strong, grass moderate, house dust mite year-round, but DKK 20-30m of wholesaler advance stocking pulled into Q3 ahead of Q4 may reverse. In Germany, Europe's largest market, a mandatory rebate increase from 1 January 2027 is being mitigated but the political outcome is opaque; management is planning for the full hit in forecasts, with only upside if exemptions materialize.
Japan and China provide large long-term upside, partly offset by declining SCIT/SLIT drops - OPPORTUNITY/BAD: International tablet growth was aided by a step-up in Japan shipments/royalties, +47%, as in-market CEDARCURE sales accelerated on improved Torii API supply, while Japan's marketing authorization transfer to Shionogi in February 2027 is expected to be supportive. SCIT/SLIT drops combined fell 6% globally to DKK 527m/30% of revenue due to normalized shipments after extraordinary China SCIT shipments last year, reflecting patient migration to tablets. In China, ACARIZAX Phase III met its primary endpoint with 19.1% relative difference vs placebo, consistent efficacy/safety and high compliance; filing with partner GenSci is targeted as soon as possible in H1 2027, with a possible launch toward end-2028 for adults only - pediatric expansion still unclear - against a market of ~100m house dust mite allergy sufferers but <1m treated, making this a major future opportunity if approved.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$19.85 Billion
Enterprise Value$18.32 Billion
Annual dividend$0.14
Dividend yield0.64%
Earnings per Share$1
Beta0.43
Outstanding Shares220,571,854

Return

Return on Equity19.30%ROE
Return on Assets13.70%
Return on Invested Capital22.05%

Valuation & Multiples

P/E Ratio40.72P/E Ratio
PEG266.39PEG
Price to Sales2.81Price to Sales
Price to Book Ratio2.81Price to Book Ratio
Enterprise Value to Revenue2.59
Enterprise Value to EBIT9.63
Enterprise Value to Net Income13
Total Debt to Enterprise0.03
Debt to Equity0.07Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About ALK-Abelló A/S

2,721 employees
CEO: Peter Halling

Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe,...

Questions & Answers